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Abstract: Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with 
either a progressive (10%–15%) or relapsing-remitting (85%–90%) course. The pathological 
hallmarks of MS are lesions of both white and grey matter in the central nervous system. The 
onset of the disease is usually around 30 years of age. The patients experience an acute focal 
neurologic dysfunction which is not characteristic, followed by partial or complete recovery. 
Acute episodes of neurologic dysfunction with diverse signs and symptoms will then recur 
throughout the life of a patient, with periods of partial or complete remission and clinical stability 
in between. Currently, there are several therapeutic options for MS with disease-modifying 
properties. Immunomodulatory therapy with interferon beta-1b (IFN-β1b) or -1a, glatiramer 
and natalizumab shows similar efficacy; in a resistant or intolerant patient, the most recently 
approved therapeutic option is mitoxantrone. IFN-β1b in patients with MS binds to specific 
receptors on surface of immune cells, changing the expression of several genes and leading to 
a decrease in quantity of cell-associated adhesion molecules, inhibition of major histocompat-
ibility complex class II expression and reduction in inflammatory cells migration into the central 
nervous system. After 2 years of treatment, IFN-β1b reduces the risk of development of clinically 
defined MS from 45% (with placebo) to 28% (with IFN-β1b). It also reduces relapses for 34% 
(1.31 exacerbations annually with placebo and 0.9 with higher dose of IFN-β1b) and makes 
31% more patients relapse-free. In secondary-progressive disease annual rate of progression 
is 3% lower with IFN-β1b. In recommended doses IFN-β1b causes the following frequent 
adverse effects: injection site reactions (redness, discoloration, inflammation, pain, necrosis 
and non-specific reactions), insomnia, influenza-like syndrome, asthenia, headache, myalgia, 
hypoesthesia, nausea, paresthesia, myasthenia, chills and depression. Efficacy of IFN-β1b in 
relapsing-remitting MS is higher than that of IFN-β1a, and similar to the efficacy of glatiramer 
acetate. These facts promote IFN-β1b as one of the most important drugs in the spectrum of 
immunological therapies for this debilitating disease.
Keywords: multiple sclerosis, interferon beta 1b, mechanism of action, efficacy, safety
Introduction
Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with 
either progressive (10%–15%) or relapsing-remitting (85%–90%) course. Essential 
for diagnosis of its relapsing-remitting form is dissemination of clinical episodes 
in time (two or more episodes) and space (more than one focal lesion). Nowadays, 
diagnosis is routinely confirmed by magnetic resonance imaging, the diagnostic test 
with 95% sensitivity.1
Prevalence of MS varies geographically, and is more common in Western 
  European and North American countries.2 The most recent estimation of prevalence Journal of Inflammation Research 2010:3 26
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in USA was 100 symptomatic MS patients per 100,000 
inhabitants,3 and prevalence in England is even higher 
(118/100,000).4 Prevalence of MS in the Middle East is 
much lower, ranging from 4/100,000 in Saudi Arabia 
and Libya to 39/100,000 in Jordan and 31.15/100,000 in 
Kuwait.5 Low prevalence was also recorded in Panama 
(5.2/100,000),6 with a female:male ratio of 8:1. Data on 
prevalence of MS are not available for the majority of 
Asian countries; however, a study from Japan reported a 
prevalence of 8.57/100,000, and studies in the Parsi com-
munity in India showed a prevalence of 21 to 58/100,000 
inhabitants.7 Such incomplete data led to a conclusion that 
prevalence of MS increases with latitude in both hemi-
spheres,2 but with obvious exceptions, like Israel (with MS 
prevalence of 46.2/100,000),7 suggesting that prevalence 
of MS in a country depends more on national and racial 
origin of its inhabitants than on its latitude.
The male:female ratio among patients with MS ranges 
from 2.4:1 in Spain,8 through 1.64:1 in Israel,7 1:2.25 in 
India7 and 1:2.3 in Norway,9 to 1:5 in Malaysia7 and 1:8 in 
Panama.6 Average age of onset is between 25 and 35 years 
of age (32.6 years in Spain,8 33 years in Japan,7 29 years in 
China,7 27 years in India,7 and 34.7 years in Kuwait7).
Pathology and pathogenesis of MS
Both genetic background and environmental events are 
involved in the pathogenesis of MS. If a family member is 
affected by MS, the risk for his/her cousins to develop the 
disease increases in proportion to the shared genetic infor-
mation between themselves and the affected person.10 If a 
monozygotic twin develops MS, his/her brother or sister 
have 200 times greater risk of developing MS than members 
of the general population. Among the environmental fac-
tors, vitamin D deficiency and Epstein-Barr virus infection 
were the only ones for which causal links with MS were 
confirmed.10,11
The pathological hallmarks of MS are lesions of both 
white and grey matter in the central nervous system.12 Early 
in our understanding MS, it was considered that myelin-spe-
cific, activated CD4+ T lymphocytes migrate from blood to 
brain tissue, bind to antigenic peptides presented by antigen 
presenting cells in the brain, clonally expand, and then attack 
oligodendrocytes, destroying myelin.13 Now we know that 
neurons degenerate in the gray matter as well, and that this 
process is a major pathological correlate of clinical disabil-
ity.13 Neurons die due to loss of myelin protection, direct 
toxic action of immune cells, diminution of trophic support, 
metabolic changes and altered signaling.13
Clinical course of MS
The onset of the disease is usually around 30 years of age. 
The patients experience an acute focal neurologic dysfunction 
which is not characteristic, followed by partial or complete 
recovery. Acute episodes of neurologic dysfunction with 
diverse signs and symptoms will then recur throughout the 
life of a patient, with periods of partial or complete remis-
sion and clinical stability in between.14 The majority of the 
patients (about 80%) have such relapsing-remitting type 
of MS (RRMS) in the beginning, which after 10 or more 
years is followed by progressive clinical disability with or 
without superimposed relapses and remissions (secondary 
progressive MS [SPMS]). In about 20% of the patients the 
disease is progressive from the beginning, sometimes with 
superimposed relapses and remissions (primary progressive/
relapsing MS [PPMS/PRMS]).15 Neurological impairment in 
the patients caused by the disease is quantified by the Kurtzke 
Expanded Disability Status Scale (EDSS)16 score: EDSS 
score from 0.0 to 2.5 (no or few limitations in mobility), 
EDSS 3.0 to 5.5 (moderate limitations in mobility), EDSS 
6.0 to 7.5 (walking aid or wheelchair necessary), EDSS 8.0 
to 9.5 (confined to bed) and EDSS 10 (death).
Therapy of MS
Currently, there are several therapeutic options for MS with 
disease-modifying properties.17 A few preparations of inter-
feron beta (IFN-β) showed efficacy in decreasing frequency 
of relapses, especially if given early in the course of the 
disease; however, the disease progression to disability was 
not slowed. When compared head-to-head, different prepa-
rations of IFN-β showed similar efficacy in the majority of 
clinical trials, with a slight dominance of interferon beta-1b 
(IFN-β1b). Glatiramer acetate, a putative neurotrophic factor, 
has shown almost the same efficacy as IFN-β, and is used 
mostly when therapy with IFN-β is no longer possible, due 
to emergence of neutralizing antibodies against it.
Natalizumab, a humanized monoclonal antibody directed 
against α4-integrin, a protein present on leukocytes, reduces 
transmigration of these cells to inflamed areas of brain. 
It reduces relapse rate in MS patients to a similar extent 
as IFN-β and glatiramer, but serious adverse effects of the 
drug recorded in a few patients, fatal progressive multifocal 
leukoencephalopathy, led to restriction of natalizumab’s use 
to cases which are resistant to treatment with both IFN-β 
and glatiramer.17
After immunomodulatory therapy with IFN-β, glat-
iramer and natalizumab loses its efficacy in a patient with 
MS or he/she becomes intolerant to it, the only approved Journal of Inflammation Research 2010:3 27
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therapeutic option is mitoxantrone.18 Mitoxantrone is an 
immunosuppressant with a similar efficacy to immuno-
modulatory drugs, but with serious adverse effects such as 
cardiomyopathy or secondary leukemia. Its use is limited 
to patients with MS no longer responsive to immunomodu-
lators, and its cumulative maximal dose must not exceed 
100 mg/m2, in order to avoid toxicity. Before each admin-
istration of mitoxantrone, an ultrasonography of heart is 
mandatory in order to detect early adverse effects on the 
myocardium and stop further therapy with the drug.
IFN-β1b preparations
A new preparation of IFN-β1b for subcutaneous adminis-
tration (Extavia®; Novartis Pharmaceuticals UK, Limited) 
was approved for use in humans by the European Medicines 
Agency (EMEA) in May 2008, and by the Food and Drug 
Administration (FDA) in United States in August 2009, 
as a biosimilar drug (the original preparation of IFN-β1b, 
Betaseron® [Chiron corporation, Berlex, Inc., Schering 
AG] had been approved for human use for many years, and 
almost all clinical trials using IFN-β1b were conducted with 
  Betaseron®). Extavia® is a recombinant IFN-β1b produced 
by genetic engineering from a strain of Escherichia coli. 
Given subcutaneously in a dose of 250 µg every other day, 
Extavia® is used for treatment of patients with a single 
demyelinating event with an active inflammatory process 
and with high risk of developing clinically definite MS, and 
for patients with severe RRMS (2 relapses in 2 years) or 
active SPMS.19
Pharmacokinetics and  
mechanism of action
After subcutaneous administration, IFN-β1b is slowly and 
irregularly absorbed (maximum serum levels are measured 
1–8 hours after injection), with an absolute bioavailability 
of 51%. It is distributed in an extracellular compartment, 
and degraded by the reticular-endothelial system in the liver. 
Total IFN-β1b clearance is about 30 mL⋅min–1⋅kg–1 and serum 
half-life around 5 hours.20,21
IFN-β1b in patients with MS binds to its specific receptors 
on surface of cells in the immune system, and then changes 
the expression of several genes. The expression of some 
genes is suppressed, leading to a decrease in quantity of 
cell-associated adhesion molecules, inhibition of major 
histocompatibility complex class II expression, and reduc-
tion in inflammatory cells migration into the central nervous 
system. Synthesis of proinflammatory cytokines is inhibited, 
and production of immunosuppressive ones is increased. 
Finally, T cells which attack neural structures, are inhibited 
by IFN-β1b22 (Figure 1).
Efficacy
efficacy in RRMS
Efficacy of IFN-β1b was tested in several placebo-controlled, 
randomized, double-blind, multicenter trials. In a phase 3 trial 
conducted by the IFN-β Multiple Sclerosis Study Group23 
IFN-β1b was given subcutaneously (250 µg or 50 µg every 
second day) to 372 patients with EDSS score less than 5.5 
and at least 2 relapses in the last 2 years. The patients were 
treated for 2 years, and IFN-β1b reduced relapses (but only 
when given in higher dose – 250 µg) for 34% (1.31 exacer-
bations annually with placebo and 0.9 with higher dose of   
IFN-β1b) and made 31% more patients relapse-free for 
the study period (16% relapse-free with placebo and 25% 
relapse-free with IFN-β1b). The following adverse events 
were related to IFN-β1b: myalgia, sweating, malaise, fever 
and injection-site reactions, like redness and pain. Injection-
site reactions were the most frequent adverse events, occur-
ring at rate close to 70%, but also relatively mild. In this 
study, researchers noted emergence of neutralizing antibod-
ies against IFN-β1b in blood of the patients who received 
this drug for prolonged periods. Up to 47% of the patients 
produced neutralizing antibodies, and became less respon-
sive to IFN-β1b after 18 months of therapy. The study was 
extended for 3 years,24 confirming sustainability of reduction 
in relapses after the higher dose (250 µg).
efficacy in initial acute  
neurological dysfunction
A large randomized, placebo-controlled, double-blind, mul-
ticenter study was conducted in 18 European countries25 on 
483 patients, to test whether early treatment with 250 µg of 
IFN-β1b (within 60 days of initial acute neurological dys-
function) will slow down progression of clinically isolated 
neurological event to clinically defined MS. After 2 years 
of treatment, IFN-β1b reduced the risk of development 
of clinically defined MS from 45% (with placebo) to 28% 
(with IFN-β1b). IFNβ-1b also prolonged the time to second 
  neurological event by 363 days (255 days in the placebo 
group, 618 days in the IFNβ-1b group).20 The study was 
extended for 3 more years, and all patients received IFNβ-1b, 
with the aim of exploring the effect of the drug on progression 
of disability.26 After 3 years, 37% of the patients who were 
receiving IFNβ-1b from the very beginning developed clini-
cally defined MS, compared with 51% of the patients who 
were at first on placebo. Also, early treatment with IFNβ-1b Journal of Inflammation Research 2010:3 28
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resulted with only 16% percent of patients who developed 
progression of disability, while 24% of patients who were at 
first on placebo and later on IFNβ-1b experienced progres-
sion of EDSS score.
efficacy in SPMS
In two studies (European27 and North American28) IFN-β1b 
(250 µg subcutaneously every second day, for 2 years) was 
tested in patients with SPMS. Only in the European study 
time to increase in the EDSS score for 1 point was longer 
in IFN group compared with placebo group, ie, annual rate 
of progression was 16% in IFN group compared with 19% 
in placebo group. The difference was not significant in the 
North American trial. Also, the mean annual relapse rate in 
the European study was lower in the IFN-β1b group (0.42) 
than in placebo group (0.63). Despite conflicting results 
of these two studies, IFN-β1b was approved by the FDA 
and the EMEA for treatment of SPMS.
Comparison with IFN-β1a
The efficacy of IFN-β1b in MS was compared with effi-
cacy of IFN-β1a in 156 patients with RRMS. The patients 
with initial value of EDSS score less than 4 were followed 
for 1229 and 1830 months, and relapse rate was the primary 
  outcome. Although the relapse rate before enrollment of the 
patients was similar in both IFN-β1a and IFN-β1b group, 
after 12 months of treatment relapse rate in IFN-β1b group 
was significantly lower (0.61 per year) than relapse rate in 
IFN-β1b group (0.85 per year). Besides, after 12 months of 
treatment, only IFN-β1b significantly reduced the EDSS 
score. Dominance of IFN-β1b over IFN-β1a was maintained 
after 18 months of follow-up.30
Higher efficacy of IFN-β1b compared to IFN-β1a was 
also shown in a multicenter, randomized clinical trial with 
188 patients with RRMS.31 The patients were treated for 
2 years, with either 30 µg of IFN-β1a per week subcutane-
ously, or with 250 µg of IFN-β1b every other day, subcuta-
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neously. After 2 years, 51% of study patients who received 
IFN-β1b remained relapse-free compared to 36% of study 
patients who were given IFN-β1a (relative risk of relapse 
0.76).
Comparison with glatiramer acetate
When compared with glatiramer acetate in patients with 
RRMS, IFN-β1b showed similar efficacy. In a large, 
randomized, prospective, multicenter clinical trial32 with 
2447 patients suffering from RRMS, 3-year therapy with 
250 µg of IFN-β1b every other day, subcutaneously, led 
to the same relapse rate as 500 µg of IFN-β1b every other 
day, subcutaneously, or 20 µg of glatiramer acetate subcu-
taneously, every day. Small clinical study with 75 patients, 
which compared IFN-β1b with glatiramer in patients with 
RRMS, had for primary outcome number of combined 
active lesions on NMR per patient per scan during the first 
year, including all enhancing lesions and non-enhancing 
new T2/fluid-attenuated inversion recovery lesions, and for 
secondary outcomes the number of new lesions and clinical 
exacerbations over 2 years. After completion of the study, 
there were no differences among the groups in new lesions 
or clinical relapses for 2 years.33
Dosing schedule of IFN-β1b
Patients with RRMS should receive initially 62.5 µg subcu-
taneously every other day for 3 doses; then the dose should 
be doubled and given every other day for the next 3 occa-
sions. The following 3 doses are given also every other day 
subcutaneously, and are 3 times higher than the initial dose. 
Finally, the patients continue to receive 250 µg every other 
day subcutaneously, for approximately 5 years. The dose of 
250 µg every other day was shown to be more effective in 
clinical trials than either the lower or higher doses.23–25,27,28 
It is not known yet whether the therapy should be continued 
after 5 years.17,19
Safety and tolerability
In recommended doses IFN-β1b causes the following   
frequent adverse effects (frequency is given in parenthesis): 
injection site reactions (redness, discoloration, inflam-
mation, pain, necrosis and non-specific reactions) (85%), 
insomnia (31%), influenza-like syndrome (34%), asthenia 
(34%), headache (32%), myalgia (26%), hypoesthesia (26%), 
nausea (16%), paresthesia (16%), myasthenia (11%), chills 
(8%), depression (8%), back pain (5%), increased liver 
enzymes (11%), lymphopenia (11%), fever (5%), and pain 
in extremities (3%).34,35 In pediatric populations, the most 
common adverse events recorded in clinical trials are influ-
enza-like syndrome (35%), abnormal liver function tests 
(26%), and injection site reactions (21%).36 During treatment 
with IFN-β1b, a number of patients develop neutralizing anti-
bodies; however, their clinical significance was not proven in 
clinical studies, making the utility of measuring neutralizing   
antibodies uncertain,37 leaving decisions about treatment with 
IFN-β1b to be made on clinical grounds.38 Apart from neutral-
izing antibodies, about 7% of patients during treatment with 
IFN-β1b develop auto-antibodies, primarily against thyroid and 
hepatic structures.39 However, emergence of the auto-antibodies 
was not linked to thyroid or liver function alterations.40
Although there are no published studies of interactions 
between IFN-β1b and other drugs, there are reports that IFNs 
reduce the activity of hepatic cytochrome P450-dependent 
enzymes.19 Therefore, one should be careful when using 
IFN-β1b in combination with drugs which are metabolized 
by the cytochrome P450 system, and whose therapeutic 
index is narrow.
Patients receiving IFN-β1b perceive depression,   
influenza-like reactions and pain due to injection site reac-
tions as most disturbing.41 When starting an IFN-β1b therapy, 
a treatment discontinuation rate ranging from 14%–44% could 
be expected.42 However, there is a considerable inter-individual 
variation among patients in perception of both the systemic 
and local side-effects, which is why it is important to identify 
early the patients who need more support or other interven-
tions to maintain compliance.43 Patient adherence is improved 
dramatically if the drug is administered subcutaneously by 
auto-injectors; besides, if the dose is gradually increased at the 
start of the treatment, if ibuprofen is used prophylactically and 
the drug is administered in the evening, the patients are more 
compliant.37 The patients with MS dependent on a wheelchair 
are at increased risk to become non-adherent to the treatment 
due to the adverse effects of IFN-β1b.
If a patient receiving IFN-β1b becomes depressed, treat-
ment of the depression with either psychotherapy or antide-
pressant medication decreases risk of discontinuing IFN-β1b 
by about 4.4-fold.44 Psychotherapy is used as a treatment 
option more frequently in university and academic group 
practice-based MS clinics than in a regular health system.
Cost/effectiveness of IFN-β1b
Because of the considerable cost of IFN-β1b therapy its 
cost/effectiveness is still an open issue, which depends on 
duration of therapy, an accurate estimate of long-term benefit 
and prices of health services in health care settings. In US 
health care settings, if IFN-β1b is given for the lifetime of a Journal of Inflammation Research 2010:3 30
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patient, incremental cost per quality-adjusted life year gained 
(compared to symptom management alone) is $310,691, 
which is within the range of incremental cost/effectiveness 
recorded for other biologic agents for MS ($258,465, $303,968 
and $416,301 for subcutaneous glatiramer, intra-muscular   
IFN-β1a and subcutaneous IFN-β1a, respectively).45 If the 
costs are calculated per relapse avoided in patients with 
RRMS, IFN-β1b, subcutaneous IFN-β1a and glatiramer 
are more favorable than intra-muscular IFN-β1a ($87,061; 
$80,589 and $88,310; respectively).46 When IFN-β1b is used 
in some of the European Union (EU) countries for 20 years, 
the costs per quality-adjusted life-year gained will be less 
than  50,000. Large differences in costs between the US and 
the EU could be explained by much higher prices of drug 
administration services in the USA.47 However, if IFN-β1b and 
other biologic agents are used for patients in a country passing 
through socio-economic transition, neither IFN-β1b nor other 
biologic agents are cost/effective, due to extremely low prices 
of relapse treatment, which is prevented by IFN-β1b.48
Tolerance to IFN-β1b
After at least 1 year of IFN-β1b therapy,49 about one fifth 
of the patients with MS develop tolerance to this drug, 
manifested as an increase in the relapse rate.50 The tolerance 
correlates well with emergence of neutralizing antibodies, 
which are produced by the patient’s immune system and 
bind to IFN-β1b, preventing its action.51 It was noted that 
this tolerance spontaneously abates after several years of 
continuous treatment, coinciding with disappearance of 
neutralizing antibodies from the patients’ sera.20 Therefore, a 
finding of neutralizing antibodies against IFN-β1b in serum 
of MS patients is not an indication for discontinuing therapy 
with this valuable drug.
Conclusions
Extavia®, an IFN-β1b for subcutaneous self-administration, 
was recently approved for treatment of relapsing-remitting or 
active secondary progressive MS, thus enlarging the spectrum 
of immunological therapies for this debilitating disease. Its 
efficacy in RRMS is higher than that of IFN-β1a, and simi-
lar to the efficacy of glatiramer acetate. Higher efficacy and 
similar safety compared with other drugs of the same class, 
mean that IFN-β1b has a significant segment of the drug 
market for MS, which is shared between the older product 
Betaseron® and Extavia®. Considering the high incidence of 
injection site reactions to IFN-β1b, a future target should be 
the development of an IFN-β1b preparation with improved 
local tolerability and maintained systemic efficacy.
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